GlassScriptPhysician profile
Heather Lynn Maggio
NPI 1922634757
$6,410.84
in general payments reported to CMS, 2019-2025
37 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,361 · 2022: $510 · 2023: $1,632 · 2024: $1,655 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,167 · Education: $372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,167.26 |
| Education | $371.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,018.74 | 2021-2025 | Tagrisso, Imfinzi, Calquence |
| Amgen INC. | $658.22 | 2021-2023 | Kyprolis, Blincyto |
| Genzyme Corporation | $612.72 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $545.07 | 2021-2025 | Opdivo, Opdualag |
| Incyte Corporation | $504.50 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $348.14 | 2021-2023 | Tukysa, Adcetris |
| Janssen Biotech, INC. | $331.08 | 2024-2025 | Erleada, Balversa, Akeega |
| Astellas Pharma US INC | $300.91 | 2021-2025 | Padcev, Cresemba, Vyloy |
| Daiichi Sankyo INC. | $252.48 | 2024-2025 | Enhertu, Datroway |
| Abbvie INC. | $172.38 | 2023-2024 | |
| Exelixis INC. | $171.11 | 2021-2025 | Cabometyx |
| Gilead Sciences, INC. | $162.30 | 2023-2025 | Trodelvy |
| Tactile Systems Technology INC | $160.01 | 2021-2024 | Flexitouch Plus, Entre Plus |
| Servier Pharmaceuticals LLC | $124.99 | 2021 | |
| Merck Sharp & Dohme LLC | $119.03 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $111.33 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $80.34 | 2023-2024 | Libtayo |
| Beigene USA, INC. | $63.72 | 2022-2023 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $61.46 | 2023-2025 | Onivyde, Tazverik |
| Emd Serono, INC. | $61.22 | 2023-2025 | Bavencio |
| Genentech USA, INC. | $54.32 | 2024-2025 | Phesgo, Tecentriq, Tecentriq Hybreza |
| Lilly USA, LLC | $46.00 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacosmos Therapeutics INC. | $41.60 | 2023-2025 | Monoferric |
| Array Biopharma INC | $38.00 | 2022-2023 | Mektovi, Xalkori, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $36.16 | 2023 | Imbruvica, Epkinly |
| Pfizer INC. | $35.66 | 2024 | |
| Fresenius Kabi USA, LLC | $29.88 | 2025 | |
| Genmab U.S., INC. | $29.61 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $20.42 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $18.82 | 2025 | |
| Taiho Oncology, INC. | $18.41 | 2023 | |
| Beone Medicines USA, INC. | $18.29 | 2025 | Tevimbra |
| Apellis Pharmaceuticals, INC. | $17.93 | 2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $17.60 | 2023 | Ultomiris |
| Karyopharm Therapeutics INC. | $15.84 | 2024 | Xpovio |
| Glaxosmithkline, LLC. | $14.55 | 2025 | Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Maggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.